Skip to content
The impact of drug price controls on innovation, market distortions caused by pharmacy benefit managers (PBMs), and the importance of accelerated approval came up […]
House 2024 health budget hearings touch on price controls and PBMs Read More »
On March 27, heads of the Food and Agriculture Organization (FAO), the U.N. Environment Programme (UNEP), the World Health Organization (WHO), and the U.N.-backed
U.N.’s ‘One Health’ approach aims to unite against zoonotic diseases Read More »
Legislation that has been reintroduced in the Senate and has the support of the Biotechnology Innovation Organization (BIO) is set to enhance research, an
R&D in biotech gets a boost with reintroduced bill Read More »
The Accelerated Approval pathway was established by the U.S. Food and Drug Administration (FDA) in the 1990s to boost R&D for HIV/AIDS, and the
I am BIO Podcast: Accelerated Approval, accelerating hope Read More »
According to a recent report from the Centers for Disease Control and Prevention (CDC), drug-resistant Candida auris (C. auris) fungus cases “spread at an
Drug-resistant C. auris fungi cases tripled in 2021 says CDC Read More »
The Department of Health and Human Services (HHS) and Department of Commerce (DOC) will investigate using Bayh-Dole march-in rights as a way to control
HHS investigating using Bayh-Dole march-in rights for price controls Read More »
Following her appearance before the Senate Finance Committee on Thursday, U.S. Trade Representative Ambassador Katherine Tai revisited the administration’s trade policy agenda on Friday
Biotech corn in the spotlight; USTR pledges to use all USMCA tools Read More »
The Senate Commerce Committee approved legislation yesterday which prohibits pharmacy benefit managers (PBMs) from pocketing the rebates they collect from drug makers. The bill
PBM Transparency Act now heads to full Senate Read More »
During a hearing Thursday, March 23, members of the Senate Finance Committee urged U.S. Trade Representative (USTR) Ambassador Katherine Tai to take action regarding
Mexico corn ban and TRIPS waiver dominate discussion in USTR hearing Read More »
Government policy impacting biotech—including drug price controls, pharmacy benefit managers (PBMs), accelerated approval, and support for new antibiotics—received a public airing this week when
